Tandem Diabetes Care | TNDM

Stock Price
12.58
Daily Change
0.19 1.53%
Monthly
-12.58%
Yearly
-70.33%
Q3 Forecast
12.48

Peers Price Chg Day Year Date
Abbott 132.94 0.13 0.10% 16.68% Sep/05
Align Technology 139.12 4.42 3.28% -37.08% Sep/05
AtriCure 35.38 -0.28 -0.79% 34.83% Sep/05
Baxter International 24.42 0.84 3.56% -37.34% Sep/05
Becton, Dickinson and Co. 192.39 1.13 0.59% -17.28% Sep/05
Boston Scientific 107.22 -0.07 -0.07% 31.36% Sep/05
Cooper Companies 68.09 0.09 0.13% -36.13% Sep/05
Dexcom 80.51 -0.25 -0.31% 17.11% Sep/05
Edwards Lifesciences 80.94 -0.02 -0.02% 21.19% Sep/05
Globus Medical 60.60 0.31 0.51% -13.42% Sep/05
Integra LifeSciences 15.99 0.34 2.17% -13.57% Sep/05
ICU Medical 131.24 5.61 4.47% -19.15% Sep/05
Intuitive Surgical 466.86 12.34 2.72% -1.06% Sep/05
J&J 178.43 -0.33 -0.18% 8.51% Sep/05
Eli Lilly 727.21 -15.70 -2.11% -19.48% Sep/05
Masimo 147.19 4.18 2.92% 31.97% Sep/05
Medtronic 92.93 0.13 0.14% 3.32% Sep/05
Merit Medical Systems 92.97 0.82 0.89% -3.74% Sep/05
Insulet 348.43 1.96 0.57% 62.25% Sep/05
Roche Holding 274.20 -1.50 -0.54% 2.62% Sep/06
Stryker 392.31 -2.03 -0.51% 9.17% Sep/05
Teleflex 130.70 1.61 1.25% -46.61% Sep/05
Tandem Diabetes Care 12.58 0.19 1.53% -70.33% Sep/05
Zimmer Biomet Holdings 105.73 0.97 0.93% 0.76% Sep/05

Indexes Price Day Year Date
USND 21700 -7.31 -0.03% 30.01% Sep/05
US2000 2391 11.44 0.48% 14.33% Sep/05

Tandem Diabetes Care traded at $12.58 this Friday September 5th, increasing $0.19 or 1.53 percent since the previous trading session. Looking back, over the last four weeks, Tandem Diabetes Care gained 12.58 percent. Over the last 12 months, its price fell by 70.33 percent. Looking ahead, we forecast Tandem Diabetes Care to be priced at 12.48 by the end of this quarter and at 12.17 in one year, according to Trading Economics global macro models projections and analysts expectations.

Tandem Diabetes Care, Inc. is a medical device company. The Company is engaged in designing, developing and commercialization of products for people with insulin-dependent diabetes. The Company’s manufacturing, sales and support activities principally focus on its flagship pump platform, the t:slim X2 Insulin Delivery System (t:slim X2), and its product offerings. The t:slim X2 is based on its technology platform and is capable of remote feature updates and is designed to display continuous glucose monitoring (CGM) sensor information directly on the pump home screen. Its products also include Basal-IQ technology and Control-IQ technology. The Basal-IQ technology is a predictive low glucose suspend feature that is designed to temporarily suspend insulin delivery to help reduce the frequency and duration of hypoglycemic events. Its Control-IQ technology is a hybrid-closed loop feature, designed to help increase a user's time in targeted glycemic range.